Jun. 15 at 1:00 PM
Citizens on
$KURA said: We reiterate our Market Outperform rating and
$24 price target for Kura Oncology based on a discounted EPS and revenue multiple analysis.
$BMY $SNDX AMGN ABBV - RHHBY RVMD
Citizens added—Recently at EHA, Kura and partner, Kyowa Kirin, presented updated KOMET-007 data evaluating zifto + 7+3 in 1L NPM1-m and KMT2A-r AML, expanding the dataset to 99 patients (vs. 71 at EHA 2025).
The EHA 2026 update shifted the narrative from depth to duration, with median CRc duration not reached in NPM1-m, 12.0 months in KMT2A-r and mOS not reached in either, with 12-month OS rates of 94% and 71% respectively, easily trouncing benchmarks from 7+3 alone.
With signs pointing to a strong KOMZIFTI launch, the frontline AML trials fully funded, the FTI program progressing in the clinic, and a cash position of
$580.8MM, we believe Kura shares represent an attractive investment opportunity.
